Compare DINO & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DINO | BIO |
|---|---|---|
| Founded | 1947 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Laboratory Analytical Instruments |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 8.7B |
| IPO Year | N/A | N/A |
| Metric | DINO | BIO |
|---|---|---|
| Price | $49.55 | $305.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | $59.40 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 2.3M | 189.5K |
| Earning Date | 02-18-2026 | 02-12-2026 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | ★ 21.43 | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $26,905,000,000.00 | $2,557,500,000.00 |
| Revenue This Year | N/A | $1.62 |
| Revenue Next Year | $1.92 | $2.26 |
| P/E Ratio | $24.18 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.66 | $211.43 |
| 52 Week High | $56.58 | $373.69 |
| Indicator | DINO | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 40.79 |
| Support Level | $47.80 | $306.52 |
| Resistance Level | $51.21 | $316.63 |
| Average True Range (ATR) | 1.64 | 9.57 |
| MACD | 0.25 | -1.13 |
| Stochastic Oscillator | 68.06 | 14.79 |
HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 300 distributors and 1,500 wholesale branded sites across 30 states. It also owns and operates 4,400 miles of petroleum product pipelines and terminals principally in the southwestern United States.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.